son of T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GeoDude who wrote (400)	1/5/2000 10:48:00 PM
From: scaram(o)uche	Read Replies (1) of 673

LIA: This molecule came out of old work from ImmunoPharmaceutics, which was purchased from Synbiotics years ago. I've tried to follow the work, although Pseudo Biologist recently shocked me by informing me that 11251 is not the molecule that I've been describing for about six or seven years. - g - The market is huge. Be interested in any updates re. leverage in business plan (if any), etc that you could provide. Been a couple of years since I owned it. Some very old commentary is in the SI thread. Everybody and their brother (pharmas) have had an interest in ETA antagonists, so be sure to watch your backside. A stock that goes up on occasion. Not a "promotional" company, the blips are from sincere investor interest. Tenacity with Novastan, but is that good or bad? For selectin antagonists.... Cytel and others came to the conclusion, long ago, that duplication of function of the molecule in any given cell precludes efficacy for most indications. I hope that those conclusions are wrong, and that they have something. Doubt it, however. Didn't PDLI recently assign rights for their anti-selectin MAbs? Would not be a great sign.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next